Results 221 to 230 of about 85,257 (242)

Bevacizumab

Reactions Weekly, 2009
openaire   +2 more sources

Bevacizumab

Reactions Weekly, 2016
openaire   +2 more sources

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Annals of Oncology, 2009
David Cunningham, J ‐L Canon, A Kretzschmar   +2 more
exaly  

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Annals of Oncology, 2016
M Nagase, T Moriwaki, T Denda
exaly  

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Annals of Oncology, 2015
R Von Moos, M Frueh, P Saletti
exaly  

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Oncologist, 2012
, Antonio Anton, Marta Llanos Munoz
exaly  

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

Annals of Oncology, 2008
Charis Eng, L M Ellis, R A Wolff
exaly  

Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles

Journal of Controlled Release, 2019
Bruno Sarmento, Mansoor Amiji, Flavia Sousa   +2 more
exaly  

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Annals of Oncology, 2013
A Jakobsen, A Berglund
exaly  

Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer

Cancer Cell, 2020
Carmen Ruiz De Almodóvar, Alba Diz-Muñoz, Ying Shen   +2 more
exaly